Palvella Therapeutics Inc (PVLA)

$79.91 +0.01 (0.01%)
Market Cap 907.70M
Revenue (ttm) 0.00
Net Income (ttm) -17.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 222,300
Avg Vol 270,792
Day's Range N/A - N/A
Shares Out 11.84M
Stochastic %K 34%
Beta -0.16
Analysts Strong Sell
Price Target $185.06

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 253 1461
Address:
125 Strafford Avenue, Suite 360, Wayne, United States
prismmarketview
prismmarketview Feb. 2 at 8:59 PM
Palvella Therapeutics (NASDAQ: $PVLA) edged about 5% higher after a new systematic review in Clinical and Experimental Dermatology reinforced the mechanistic and clinical rationale for topical statins in porokeratosis, bolstering support for its QTORIN pitavastatin program alongside the ongoing Phase 3 QTORIN rapamycin effort in microcystic lymphatic malformations. https://prismmarketview.com/palvella-therapeutics-shares-rise-5-after-scientific-publication-highlights-unmet-need-in-rare-skin-disease/
0 · Reply
BioTuesdays
BioTuesdays Feb. 2 at 6:14 PM
$PVLA announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis, supporting the scientific rationale and clinical potential of its QTORIN pitavastatin for treating disseminated superficial actinic porokeratosis (DSAP) https://biotuesdays.com/2026/02/02/publication-supports-scientific-rationale-for-palvellas-qtorin-in-dsap/
0 · Reply
Quantumup
Quantumup Feb. 2 at 12:49 PM
TD Cowen⬆️ $PVLA's PT to $190 from $133 and reiterated at a Buy rating. $NVS $PFE $TEVA TD Cowen said in its note: PVLA held a successful BTD advice meeting for QTORIN rapa in cVM v. recently and intends to file for BTD shortly. The meeting was attended by sr. FDA division leadership who heard strongly supportive KOL opinion of QTORIN rapa's efficacy in cVM. We have high conviction QTORIN rapa will receive BTD in cVM, which could allow FDA alignment on a single-arm Ph3 design, expediting data and approval.
0 · Reply
Eagley3k
Eagley3k Jan. 30 at 8:21 PM
$PVLA found a support around $73. heavy volume accumulation. Time for reversal?
0 · Reply
Jcljack26
Jcljack26 Jan. 30 at 5:32 PM
$PVLA $40 off the high and half of most price targets.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 9:46 PM
$PVLA RSI: 44.31, MACD: -2.0767 Vol: 6.75, MA20: 96.45, MA50: 95.87 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
dianahilla
dianahilla Jan. 25 at 1:35 PM
$PVLA what happened?
0 · Reply
Eagley3k
Eagley3k Jan. 25 at 1:11 PM
$PVLA $TARA is there a chance if the government shuts down, data could be delayed?? Appreciate well informed investors' opinion
1 · Reply
Eagley3k
Eagley3k Jan. 23 at 9:48 PM
$PVLA got in today. seems like H&S but I'm hoping it will fail.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 21 at 6:26 AM
$PVLA Share Price: $97.67 Contract Selected: Aug 21, 2026 $100 Calls Buy Zone: $28.69 – $35.44 Target Zone: $53.60 – $65.51 Potential Upside: 76% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on PVLA
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Feb 2, 2026, 7:30 AM EST - 1 day ago

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 12 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Jan 9, 2026, 7:30 AM EST - 25 days ago

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Jan 7, 2026, 7:30 AM EST - 27 days ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Dec 23, 2025, 10:43 AM EST - 6 weeks ago

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Dec 16, 2025, 7:30 AM EST - 7 weeks ago

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Dec 15, 2025, 6:00 AM EST - 7 weeks ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Nov 6, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Nov 5, 2025, 6:00 AM EST - 3 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

Nov 4, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Oct 13, 2025, 7:30 AM EDT - 4 months ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Sep 24, 2025, 6:00 AM EDT - 4 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Sep 22, 2025, 7:30 AM EDT - 4 months ago

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Sep 17, 2025, 7:30 AM EDT - 4 months ago

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Sep 15, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Sep 3, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Jun 18, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Jun 9, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 27, 2025, 8:00 AM EDT - 9 months ago

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 8, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

May 5, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Apr 23, 2025, 4:15 PM EDT - 10 months ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 22, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Apr 11, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Mar 18, 2025, 8:30 AM EDT - 11 months ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Feb 10, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Dec 13, 2024, 2:55 PM EST - 1 year ago

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

prismmarketview
prismmarketview Feb. 2 at 8:59 PM
Palvella Therapeutics (NASDAQ: $PVLA) edged about 5% higher after a new systematic review in Clinical and Experimental Dermatology reinforced the mechanistic and clinical rationale for topical statins in porokeratosis, bolstering support for its QTORIN pitavastatin program alongside the ongoing Phase 3 QTORIN rapamycin effort in microcystic lymphatic malformations. https://prismmarketview.com/palvella-therapeutics-shares-rise-5-after-scientific-publication-highlights-unmet-need-in-rare-skin-disease/
0 · Reply
BioTuesdays
BioTuesdays Feb. 2 at 6:14 PM
$PVLA announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis, supporting the scientific rationale and clinical potential of its QTORIN pitavastatin for treating disseminated superficial actinic porokeratosis (DSAP) https://biotuesdays.com/2026/02/02/publication-supports-scientific-rationale-for-palvellas-qtorin-in-dsap/
0 · Reply
Quantumup
Quantumup Feb. 2 at 12:49 PM
TD Cowen⬆️ $PVLA's PT to $190 from $133 and reiterated at a Buy rating. $NVS $PFE $TEVA TD Cowen said in its note: PVLA held a successful BTD advice meeting for QTORIN rapa in cVM v. recently and intends to file for BTD shortly. The meeting was attended by sr. FDA division leadership who heard strongly supportive KOL opinion of QTORIN rapa's efficacy in cVM. We have high conviction QTORIN rapa will receive BTD in cVM, which could allow FDA alignment on a single-arm Ph3 design, expediting data and approval.
0 · Reply
Eagley3k
Eagley3k Jan. 30 at 8:21 PM
$PVLA found a support around $73. heavy volume accumulation. Time for reversal?
0 · Reply
Jcljack26
Jcljack26 Jan. 30 at 5:32 PM
$PVLA $40 off the high and half of most price targets.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 27 at 9:46 PM
$PVLA RSI: 44.31, MACD: -2.0767 Vol: 6.75, MA20: 96.45, MA50: 95.87 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
dianahilla
dianahilla Jan. 25 at 1:35 PM
$PVLA what happened?
0 · Reply
Eagley3k
Eagley3k Jan. 25 at 1:11 PM
$PVLA $TARA is there a chance if the government shuts down, data could be delayed?? Appreciate well informed investors' opinion
1 · Reply
Eagley3k
Eagley3k Jan. 23 at 9:48 PM
$PVLA got in today. seems like H&S but I'm hoping it will fail.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 21 at 6:26 AM
$PVLA Share Price: $97.67 Contract Selected: Aug 21, 2026 $100 Calls Buy Zone: $28.69 – $35.44 Target Zone: $53.60 – $65.51 Potential Upside: 76% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
judgeyoung2
judgeyoung2 Jan. 14 at 4:24 PM
$PVLA march
0 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 12 at 2:53 PM
$PVLA will get bought out
0 · Reply
Eagley3k
Eagley3k Jan. 9 at 7:29 AM
$PVLA when do you guys expect ph3 readout?
0 · Reply
Quantumup
Quantumup Jan. 8 at 3:52 PM
TD Cowen reiterated $PVLA Buy-$133 and said that it has 'High Conviction of Success for the Ph3 mLM QTORIN Rapa SELVA Data,' in its Preview $TARA $QNRX NVS PFE TD Cowen said in its note: Topline Ph3 mLM data of QTORIN rapa is due 1Q26. We have high conviction data will show stat sig meaningful efficacy on its mLM-IGA 1° EP on 1) compelling Ph2 mLM PoC data showing robust efficacy and good safety/tolerability, 2) clinical evidence of oral/topical rapa's efficacy in mLM, w/ no spontaneous remission in natural history, 3) similarity of the Ph3 mLM-IGA 1° EP and the CGI-C used in Ph2.
0 · Reply
ShowMeYourTickersss
ShowMeYourTickersss Jan. 7 at 1:17 PM
$PVLA Yes! Analysts are reiterating their buy ratings right before PVLA dumps $300 million worth of new stock. 🤣
0 · Reply
ShowMeYourTickersss
ShowMeYourTickersss Jan. 6 at 2:53 AM
$PVLA Drop this S-1 or prospectus already! 🔪🩸🙏
0 · Reply
vlentini
vlentini Jan. 5 at 6:15 PM
$PVLA Penso si tratti di diluizione,non c'è altra spiegazione ,non ci sono notizie negative, purtroppo credo che continueranno a diluire prima che ci siano notizie che dovrebbero essere buone.
0 · Reply
Mahvalousday
Mahvalousday Jan. 5 at 4:35 PM
$PVLA anyone know what’s going on today with Pvla ?
1 · Reply
ShowMeYourTickersss
ShowMeYourTickersss Jan. 2 at 10:14 PM
$PVLA
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 1 at 10:09 PM
Comparing trending tickers $WYY vs $PVLA: WYY dropped slightly by 2.54% to $5.37, trading below its average volume at 64.4K shares. In contrast, PVLA soared 4.80% to $104.67 on a volume of 389.5K shares, significantly above its average. While PVLA is experiencing robust trading and notable price appreciation, WYY is seeing a downturn in both its stock price and trading volume.
0 · Reply
Avocado_smash
Avocado_smash Jan. 1 at 6:57 PM
$PVLA PT: 108.97 - 113.71++ Open, trade and closed below that range, pullback might start.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 12:47 PM
$PVLA RSI: 55.42, MACD: 3.8014 Vol: 4.91, MA20: 98.84, MA50: 89.29 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply